Get notified when HAE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Impairment Of Intangible Assets (worsened) — Intangible impairment charge increased from $2.4M in FY2025 to $86.5M in FY2026, primarily related to Attune Medical acquired in April 2024.
Haemonetics posts $86.5M Attune Medical write-down as pulse field ablation erodes market
Filed May 20, 2026 · Period ending March 28, 2026 · Compared to 10-K May 21, 2025 · ~2 min read
Key Changes
-
high
Company recorded $86.5M intangible impairment on Attune Medical (acquired April 2024) as pulse field ablation adoption reduced demand for esophageal cooling devices, driving 29% operating income decline despite pricing gains.
MD&A: Operating Income & Impairment verify on EDGAR → -
high
Revenue fell 2% as $153M nonrecurring FY2025 revenue from CSL Plasma transition and Whole Blood divestiture offset Hospital segment growth; one Plasma customer now represents 13% of total revenue, up from below 10% threshold.
MD&A: Revenue Performance verify on EDGAR → -
high
Initiated patent litigation against Terumo BCT and Fresenius/Fenwal over plasma collection technology; Fenwal counterclaimed alleging Haemonetics infringes its patents, introducing legal cost and IP risk.
Notes: Legal Proceedings verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.
Partner
Trade HAE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · May 26, 2026 · How we verify